Cancer Family
Uveal Melanocytic Neoplasm
CI-CAN-00000381Explore in graph →
Non-malignant59 active trials1 approved drugs17 evidence items
- NCIt
- C205057
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000381Explore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07804186 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | recruiting | Phase 3 | 450 | IDEAYA BiosciencesINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT02678572 | Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma(FOCUS) | completed | Phase 3 | 102 | Delcath Systems Inc.INDUSTRY | 9 | Sep 10, 2026 | clinicaltrials |
| NCT06007690 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma(CoMpass) | active not recruiting | Phase 3 | 108 | Aura BiosciencesINDUSTRY | 14 | Jul 31, 2026 | clinicaltrials |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma(ATOM) | recruiting | Phase 3 | 290 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jun 30, 2026 | clinicaltrials |
| NCT01989572 | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery | completed | Phase 3 | 815 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT05987332 | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | active not recruiting | Phase 2 / Phase 3 | 420 | IDEAYA BiosciencesINDUSTRY | 13 | Feb 17, 2026 | clinicaltrials |
| NCT01983748 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | completed | Phase 3 | 200 | University Hospital ErlangenOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma(AMUM) | recruiting | Phase 3 | 100 | Gustav StalhammarOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06519266 | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases(SCANDIUM-III) | recruiting | Phase 3 | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | active not recruiting | Phase 3 | 30 | Delcath Systems Inc.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT02843386 | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma(FOTEADJ) | completed | Phase 3 | 302 | Institut CurieOTHER | 2 | Aug 31, 2022 | clinicaltrials |
| NCT00324727 | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma | completed | Phase 3 | 93 | Delcath Systems Inc.INDUSTRY | 1 | Jun 21, 2021 | clinicaltrials |
| NCT00680225 | Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma | completed | Phase 3 | 10 | New England Retina AssociatesOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT01974752 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)(SUMIT) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 11 | Jan 5, 2017 | clinicaltrials |
| NCT00036816 | Vaccine Therapy in Treating Patients With Melanoma of the Eye | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Sep 24, 2012 | clinicaltrials |
| NCT00110123 | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma | terminated | Phase 3 | 171 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 24, 2012 | clinicaltrials |
| NCT00811200 | Treatment Of Radiation Retinopathy Trial(TORR) | unknown | Phase 2 / Phase 3 | 220 | Leiden University Medical CenterOTHER | 0 | Jul 2, 2009 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials